FIELD: medicine.
SUBSTANCE: group of inventions involves a diagnostic technique for bladder cancer based on measuring the iRNA content of TRIB1 gene by PCR and a kit for implementation thereof. The higher iRNA content of TRIB1 in a provisionally involved bladder and/or urine as compared to its content in healthy tissue and/or blood is used as a diagnostic character of bladder cancer.
EFFECT: group of invention enables high-reliability diagnosing of bladder cancer, including at the early stage of progressing neoplastic aberration.
2 cl, 4 tbl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR BLADDER CANCER BY CANCER-SPECIFIC MARKER TEDP1 (VERSIONS) AND KIT FOR IMPLEMENTING IT | 2011 |
|
RU2463354C1 |
| METHOD FOR ESTIMATING CLINICAL EFFECTIVENESS OF HUMAN BLADDER CANCER BY REAL-TIME PCR AND KIT FOR IMPLEMENTATION THEREOF | 2011 |
|
RU2469098C2 |
| METHOD OF DIAGNOSING URINARY BLADDER CANCER BY MEANS OF ONCOMARKER KIFC1 (VERSIONS) AND SET FOR ITS REALISATION | 2011 |
|
RU2470301C2 |
| METHOD OF ESTIMATING EFFICIENCY OF THERAPY URINARY BLADDER CANCER IN HUMANS BY METHOD OF IMMUNOFERMENTATIVE ANALYSIS | 2011 |
|
RU2468088C1 |
| METHOD OF ESTIMATING EFFICIENCY OF THERAPY OF URINARY BLADDER CANCER BY MEANS OF ONCOMARKER NUSAP1 | 2011 |
|
RU2468372C1 |
| DIAGNOSTIC TECHNIQUE FOR COLON CANCER AND KIT FOR IMPLEMENTING THEREOF | 2008 |
|
RU2374647C1 |
| DETERMINATION OF GENE ZG16 mRNK LEVEL REDUCTION AS METHOD OF LARGE INTESTING CANCER DIAGNOSTICS AND SET OF ITS REALISATION | 2009 |
|
RU2395234C1 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| DIAGNOSTIC TECHNIQUE FOR PAPILLARY CELL RENAL CARCINOMA AND SET FOR IMPLEMENTATION THEREOF | 2014 |
|
RU2605829C2 |
| METHOD OF PREDICTING THE DEVELOPMENT OF RELAPSE IN PATIENTS WITH HUMAN PAPILLOMAVIRUS AND NON-MUSCLE-INVASIVE BLADDER CANCER | 2022 |
|
RU2800265C1 |
